

Deucravacitinib Therapeutic Cheat Sheet

COMPILED BY: NAGASAI C. ADUSUMILLI, MD, MBA | REVIEWED BY: ADAM J. FRIEDMAN, MD, FAAD

TRADE NAME¹

- › Sotyktu

MECHANISM OF ACTION¹

- › Selective Tyrosine Kinase 2 (TYK2) inhibitor
- › Allosterically binds the regulatory (pseudokinase) domain of TYK2, inhibiting downstream signal transducers and activators of transcription (STATs)
- › TYK2 pairs with Janus kinase 1 (JAK1), mediating signaling of interleukin (IL)- 12, IL-23, and Type I interferon

FDA-APPROVED FOR¹

- › Adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

OFF-LABEL DERMATOLOGIC USES

- › Systemic lupus erythematosus^{2,3}
- › Cutaneous lupus erythematosus, including discoid lupus⁴
- › Oral lichen planus⁵

ADULT ORAL DOSING¹

- › 6 mg daily

ADMINISTRATION CONSIDERATIONS

- › Avoid in patients with Child-Pugh C liver impairment
- › Update age-appropriate immunizations prior to starting treatment
- › Consider prophylactic herpes zoster vaccine⁶

SIDE EFFECTS⁷

- › Most common: upper respiratory infections, headache, mouth ulceration⁷
- › Particularly notable: herpes simplex and zoster infections, acneiform eruption, liver enzyme elevations⁷

CONTRAINDICATIONS

- › Absolute contraindication: hypersensitivity to drug previously¹
- › Discontinue if serious infection develops during treatment¹
- › Discontinue if CPK is markedly elevated or rhabdomyolysis is diagnosed¹

DRUG INTERACTIONS^{1,11}

- › Avoid coadministration with isotretinoin or acitretin given the increased risk for intracranial hypertension
- › Concomitant use with antacids may impair absorption and decrease efficacy of *Sarecycline*.
- › *Sarecycline* may interfere with the bactericidal action of penicillin thus concomitant use should be avoided.
- › *Sarecycline* may increase serum levels of P-gp substrates (e.g. digoxin).
- › *Sarecycline* may depress plasma prothrombin activity, increasing bleeding risk in patients on anticoagulant therapy.

PREGNANCY AND BREASTFEEDING¹

- › No human data
- › Animal models with no embryo-fetal or post-natal lactation toxicity
- › Report any pregnancies during treatment to BMS at 1-800-721-5072.

MONITORING

- › Baseline Labs and Periodic Monitoring:
 - › Although the package insert recommends screening for TB and elevated liver enzymes and periodically checking triglycerides and CPK, an updated expert consensus panel recommends no baseline or periodic labs.⁸
 - › During treatment, consider checking CPK if rhabdomyolysis is clinically suspected

REFERENCES

1. SOTYKTU [prescribing information]. Bristol-Myers Squibb; Revised Sept 2022. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214958s000lbl.pdf. Accessed Nov 25, 2025.
2. Wegman T, Catlett I, Banerjee S, Singhal S. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase ii, randomized, double-blind, placebo-controlled trial. *Arthritis Rheumatol*. 2023 Feb;75(2):242-252. PMID: 36369798.
3. Arriens C, Morand EF, Askanase AD, et al. design of two randomized, placebo-controlled, phase 3 trials of deucravacitinib, an oral, selective, allosteric tyk2 inhibitor, in systemic lupus erythematosus. *Adv Ther*. 2025 Nov;42(11):5830-5844. PMID: 40920289.
4. Bokor LA, Martyin K, Krebs M, et al. Deucravacitinib shows superior efficacy and safety in cutaneous lupus erythematosus compared to various biologics and small molecules - A systematic review and meta-analysis. *Autoimmun Rev*. 2025 Feb 28;24(3):103723. PMID: 39694128.
5. Stolte KN, Mesas-Fernández A, Meier K, et al. TYK2 inhibition with deucravacitinib ameliorates erosive oral lichen planus. *Exp Dermatol*. 2024 Apr;33(4):e15080. PMID: 38628035.
6. Zhao K, Xiao S, Zhao Y, Tu C. Real-world safety of deucravacitinib: insights from the Food and Drug Administration Adverse Event Reporting System. *Int J Clin Pharm*. 2025 Oct;47(5):1215-1223. PMID: 40202574.
7. Armstrong AW, Lebwohl M, Warren RB, et al. Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials. *J Eur Acad Dermatol Venereol*. 2025 Jul;39(7):1336-1351.. PMID: 40045918.
8. Shah M, Burshtein J, Zakria D, et al. A Review of the safety and efficacy of deucravacitinib for plaque psoriasis: an expert consensus panel. *J Drugs Dermatol*. 2025 Feb 1;24(2):147-155. PMID: 39913225.